The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-22. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
The Buran could be fitted with four Saturn AL-31 turbofan engines and a fuel tank in its payload bay, allowing it to make its own atmospheric test flights, which began in November 1985. Also unlike the US Shuttle, it could be flown pilotlessly and landed automatically. Energia-Buran made only one orbital test flight in November 1988, but US counterintelligence baited the Soviets with disinformation about the heat shield design, and it was not reusable for repeated flight. Buran was the largest and most expensive Soviet program in the history of the Space Race, and was effectively canceled by the collapse of the Soviet Union in 1991, due to lack of funding. The Energia was also canceled at the same time, after only two flights.
After Independence, Pakistan vigorously pursued bilateral relations with other Muslim countries. The Ali brothers sought to project Pakistan as the natural leader of the Islamic world, partly due to its significant manpower and military strength. Khaliquzzaman, a prominent Muslim League leader, declared Pakistan's ambition to unite all Muslim countries into Islamistan, a pan-Islamic entity. These developments, alongside Pakistan's creation, didn't receive approval from the United States, with British Prime Minister Clement Attlee expressing a hope for India and Pakistan to reunite. However, due to a nationalist awakening in the Arab world at that time, there was little interest in Pakistan's Pan-Islamic aspirations. Some Arab countries perceived the 'Islamistan' project as Pakistan's bid to dominate other Muslim states. Pakistan's founder, Muhammad Ali Jinnah, consistently advocated for the Palestinian cause, shaping Pakistan's foreign policy to support Palestinian rights within the broader framework of Muslim solidarity. During the 1967 Arab-Israel war, Pakistan supported the Arab states and played a key role in securing Iran's backing for the Arab cause both within the U.N. and beyond. Pakistan's relations with Iran have been strained by sectarian tensions, with both Iran and Saudi Arabia using Pakistan as a battleground for their proxy sectarian war. Since the early days of the Iran–Iraq war, President Zia-ul-Haq played an important mediatory role, with Pakistan actively engaging in efforts to end the conflict.
In the drug discovery process of a 5-HT2C agonist, a pharmacophore module has been used to discover novel 5-HT2C receptor ligands. The pharmacophore has four features; one aromatic ring, two hydrophobic features and one positive ionizable feature. Figure 4 shows an example of a compound that fits the agonist pharmacophore perfectly. The nitrogen atom of piperazine fits the positive ionizable feature, the benzofuran part fits the aromatic ring and one hydrophobic, and the trifluoromethane part fits another hydrophobic feature of the pharmacophore.
Sources: en.wikipedia.org
== Research and career == In 2000 Pohl joined the faculty at Iowa State University. She spent twelve years in Iowa, eventually being made Wilkinson Professor of Chemistry and Biomedical Engineering. In 2008 she founded LuCELLa Biosciences, a spin-out company who specialise in the custom synthesis of carbohydrates. Pohl joined Indiana University Bloomington in 2012, where she was made the Professor and Joan & Marvin Carmack Chair. Pohl is interested in the synthesis and characterisation of sugars in an effort to better understand their role in biological function. By better understanding the interactions of carbohydrates, Pohl believes that she will be able to rationally design vaccinations and other therapies. She demonstrated an oligosaccharide synthesis process that involved automated solution-phase methods. The automation process involves the use of fluorocarbon tags that can be used to pattern the surfaces of tagged molecules to form carbohydrate microarrays. Pohl spent 2019 as a Fulbright Program scholar at the University of Natural Resources and Life Sciences, Vienna.
== Major subtypes == There are four major subtypes of opioid receptors. OGFr was originally discovered and named as a new opioid receptor zeta (ζ). However it was subsequently found that it shares little sequence similarity with the other opioid receptors, and has quite different function.
=== Hydrogen Isotope Analysis === Hydrogen isotope analysis is used to help reconstruct environmental change. Dinosterol is a particularly good target for such analysis because it is commonly found in high concentrations in a variety of aquatic environments and is well preserved in the sediment record. Hydrogen isotope analysis requires a purification method that achieves GC baseline resolution and is high yielding. Dinosterol coelutes with other sterols during GC; therefore a procedure for proper purification that involves reversed phase-high performance liquid chromatography (RP-HPLC) was developed by Atwood et al. The hydrogen isotope ratios in dinosterol can be used to reconstruct salinity semi-quantitatively. In a study by Schwab et al., the hydrogen isotope ratio of dinosterol was measured in suspended particles and surface sediments from the Chesapeake Bay estuary. The D/H ratio was found to decrease by 0.99 ± 0.23% per unit increase in salinity over the salinity range 10–29 PSU. The correlation between hydrogen isotopic response and salinity may result from diminished exchange of water between algal cells and their environment, lower growth rates and/or increased production of osmolytes at high salinities.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.